During the development of aggressive cancer, the epithelial-to-mesenchymal transition (EMT), characterized by a change in the expression from E-cadherin (CDH1) to N-cadherin (CDH2), enables cancer cells to acquire invasive and metastatic properties [20,21]. Here, CDH2 is linked to cancer.